HealthTap


HealthTap is a technology company delivering a suite of connected health apps. Their customers include health systems, insurance companies, and employers.
The company received Series A funding from the Mayfield Fund, Eric Schmidt’s Innovation Endeavors and Mohr Davidow Ventures
The main service offered by HealthTap is the ability to ask health questions, online and via mobile devices, to a network of U.S.-licensed physicians for free. They also offer the ability to connect immediately or by appointment with a doctor for a consultation via video conference, phone call, or text chat.
There are currently a number of versions of HealthTap available across several platforms and devices, including a version for the web along with applications for iPhone, iPad and Android.

Interactive health

Health information on the service is supplied interactively by a network of nearly 140,000 licensed doctors in good standing. HealthTap also provides the opportunity for peer review, which consists of doctors rating each other and self-identifying specializations. HealthTap says its doctor network is present in 170 countries.

Press and expansion

HealthTap has garnered media coverage in publications including The New York Times, Forbes and TIME.
HealthTap started its Medical Expert Network with U.S.-licensed OBGYN and Pediatrics physicians, which the company describes as the largest network of interactive, engaged physicians online.
In December 2011, HealthTap announced that it had secured $11.5 Million in Series A funding, led by The Mayfield Fund, Eric Schmidt’s Innovation Endeavors and Mohr Davidow Ventures.
In November 2012, HealthTap acquired the doctor directory and rating business from Avvo.
In March 2016, HealthTap acquired DocPhin, a startup designed to make finding and reading medical research easier for doctors.
In December 2017, the New Zealand Government's Auditor General launched a review into the cancelled implementation of a HealthTap-based system at the Government's Waikato District Health Board. The results of the review were overwhelmingly negative and found, amongst other things, that the platform was not fit for purpose.